Quince Therapeutics (QNCX) AI Stock Analysis

• Market Cap: $10.02M
• Dividend Yield: N/A
• Average Volume (3M): 3.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.02
• Revenue Growth: N/A
• EPS Growth: 2.26%
• Country: US
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 55,681,490
• 10 Day Avg. Volume: 7,660,344
• 30 Day Avg. Volume: 3,067,714
• PEG Ratio: -0.03
• Price to Book (P/B): 2.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: 1.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -165.02
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: $10.00
• Price Target Upside: 7042.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.76
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.26 ▲(83.57% Upside)

The score is driven primarily by very weak financial performance (no revenue, large losses, sustained cash burn, and a significantly weakened equity position with higher leverage). Technicals also weigh on the score due to a strong downtrend, while valuation is constrained by negative earnings and no dividend support.

Positive Factors

Innovative Product Pipeline

The focus on innovative treatments and a strong pipeline targeting unmet medical needs positions Quince for potential breakthroughs, enhancing long-term growth prospects.

Strategic Partnerships

Strategic partnerships with larger firms provide financial support and market access, crucial for advancing drug candidates and achieving commercialization.

Manageable Debt Levels

Low debt levels provide financial flexibility and reduce risk, allowing the company to focus resources on R&D and strategic initiatives without significant debt burden.

Negative Factors

No Revenue Generation

The lack of revenue generation highlights challenges in achieving financial sustainability and necessitates successful product commercialization to ensure long-term viability.

Consistent Losses

Persistent losses indicate operational inefficiencies and the need for effective cost management to improve margins and achieve profitability over time.

Negative Cash Flow

Negative cash flow underscores difficulties in funding operations and growth initiatives, necessitating improved cash management strategies to sustain business activities.

Quince Therapeutics Business Overview & Revenue Model

Company Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

How the Company Makes Money

Quince Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products. Revenue is generated from sales of approved drugs, milestone payments, and royalties from partnerships or licensing agreements with larger pharmaceutical companies. In addition, the company may receive funding through research grants and collaborations with academic institutions or other biotech firms. Quince Therapeutics' earnings are significantly influenced by the successful progression of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

Quince Therapeutics Financial Statement Overview

Summary

Financials are very weak: zero revenue, persistent heavy losses, and ongoing negative operating/free cash flow. Balance-sheet risk has risen as equity eroded sharply while debt increased, raising leverage and financing/dilution risk despite a modest recent improvement in cash burn.

Income Statement

The income statement remains very weak, with zero revenue across the annual periods and continued heavy losses. Profitability deteriorated from 2023 to 2024 (net loss widened materially), and TTM (Trailing-Twelve-Months) stayed deeply negative with large operating and net losses, indicating the business is still in a cash-burning development stage. A modest positive is that losses in TTM are roughly in-line with 2024, suggesting no sharp new step-down, but overall earnings power is not yet established.

Balance Sheet

Balance sheet risk increased meaningfully. Stockholders’ equity fell sharply from 2023 to 2024 and collapsed to a very low level in TTM (Trailing-Twelve-Months), while debt rose—driving leverage much higher versus prior years. Total assets are relatively stable, but the very thin equity cushion and highly negative return on equity point to elevated financing and dilution risk if losses continue.

Cash Flow

Cash generation remains weak with consistently negative operating cash flow and negative free cash flow each year and in TTM (Trailing-Twelve-Months). Cash burn improved versus 2024 (TTM free cash flow was less negative), which is a near-term positive, but cash flows still do not self-fund operations. Free cash flow roughly tracks net losses, reinforcing that losses are translating into ongoing cash outflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-119.00K	0.00	0.00	0.00	-344.00K	0.00
EBITDA	-54.74M	-35.98M	-26.82M	-50.99M	-89.97M	-78.56M
Net Income	-56.98M	-56.83M	-31.39M	-51.66M	-89.94M	-76.85M
Balance Sheet
Total Assets	109.90M	114.48M	180.20M	103.91M	133.23M	189.47M
Cash, Cash Equivalents and Short-Term Investments	26.29M	40.78M	75.06M	90.18M	106.80M	133.82M
Total Debt	17.99M	14.81M	13.81M	453.00K	1.16M	446.00K
Total Liabilities	108.84M	84.33M	95.12M	3.32M	14.64M	17.20M
Stockholders Equity	1.06M	30.15M	85.08M	100.59M	118.59M	172.26M
Cash Flow
Free Cash Flow	-38.98M	-32.16M	-18.45M	-44.17M	-63.11M	-50.87M
Operating Cash Flow	-38.50M	-31.90M	-18.29M	-44.04M	-62.93M	-50.82M
Investing Cash Flow	26.02M	21.91M	-5.76M	18.00M	58.95M	-52.43M
Financing Cash Flow	15.88M	-4.78M	143.00K	707.00K	6.81M	118.88M

Quince Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 3.06, and below the 200-day MA of 1.90, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 20.91 is Positive, neither overbought nor oversold. The STOCH value of 0.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNCX.

Quince Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADAG	53 Neutral	$138.57M	-4.58	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	47 Neutral	$153.42M	-1.60	-26.69%	―	―	25.84%
PLRX	42 Neutral	$73.12M	-0.42	-64.27%	―	―	14.19%
QNCX	40 Underperform	$10.02M	―	-247.78%	―	―	2.26%
ANEB	40 Underperform	$39.33M	-4.04	-145.11%	―	―	23.10%
GBIO	39 Underperform	$38.00M	-0.61	-80.81%	―	-17.82%	57.32%